Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Ensuring public trust in digital therapeutics: a pharmacopeial perspective | Synapse

April 1, 2021Open Access

Ensuring public trust in digital therapeutics: a pharmacopeial perspective

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

No funding supported the writing of this commentary. The author is employed by US Pharmacopeia. This article was requested by JMCP as a response to the companion Viewpoints article "Decision Makers Need an Approach to Determine Digital Therapeutic Product Quality, Access, and Appropriate Use" by Parcher and Coder (see page 536). Digital Therapeutics Alliance, which is mentioned in this article, is a member of the USP Convention.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Michael Ambrose (Thu,) studied this question.

synapsesocial.com/papers/6a191cfde035d3d8a726435e https://doi.org/https://doi.org/10.18553/jmcp.2021.27.4.533

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Value of U.S. Pharmacopeial Standards: A Review of the Literature2018 · 11 citations
2Decision makers need an approach to determine digital therapeutic product quality, access, and appropriate use2021 · 10 citations
3Health sector accreditation research: a systematic review2008 · 533 citations
4Comparative Potency and Dissolution Performance of Internationally Available Piroxicam Products1992 · 9 citations
5Impact of Accreditation on the Quality of Healthcare Services: a Systematic Review of the Literature2011 · 422 citations